ArticleCancer science2008
Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Gitogenin impedes tumorigenesis in hepatocellular carcinomaFrontiers in oncology · 2026Article
- Antimutagenic effects of a tea made from Actinidia arguta, sarunashi in Japanese, and its inhibitory effects on the formation of aberrant crypt foci induced by 1,2-dimethylhydrazine in mice.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025Article
- Drosophila NUAK functions with Starvin/BAG3 in autophagic protein turnover.PLoS genetics · 2020Article
- Sucrose nonfermenting AMPK-related kinase (SNARK) regulates exercise-stimulated and ischemia-stimulated glucose transport in the heart.Journal of cellular biochemistry · 2019Article
- NUAK2 is a critical YAP target in liver cancer.Nature communications · 2018Article
- The AMPK-related kinase SNARK regulates muscle mass and myocyte survival.The Journal of clinical investigation · 2016Article
- Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes.PloS one · 2014Article
- The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.Journal of hepatology · 2013Article
- The LKB1 complex-AMPK pathway: the tree that hides the forest.Familial cancer · 2011Review
- NUAK2: an emerging acral melanoma oncogene.Oncotarget · 2011Review
- AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance.Future medicinal chemistry · 2010Review
- Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- AMPK and SIRT1: a long-standing partnership?American journal of physiology. Endocrinology and metabolism · 2010Review
- Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes.Diabetologia · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SNF-1/5'-AMP-activated kinase (AMPK)-related kinase (SNARK) is a member of the AMPK-related kinases. Snark(+/-) mice exhibited mature-onset obesity and related metabolic disorders. Obesity is regarded as a risk factor for colorectal cancer. To investigate whether Snark deficiency is involved in tumorigenesis in the large intestine, obese Snark(+/-) mice were treated with a chemical carcinogen, azoxymethane (AOM). The incidences of both adenomas and aberrant crypt foci (ACF) were significantly higher in Snark(+/-) mice than in their wild-type counterparts 28 weeks after the completion of AOM treatment (10 mg/kg/week for 8 weeks). Furthermore, ACF formation was enhanced in Snark(+/-) mice treated with AOM for 2 weeks, suggesting that Snark deficiency contributed to the early phase of tumorigenesis. The total number of ACF was correlated with bodyweight in Snark(+/-) and Snark(+/+) mice, suggesting that obesity was a risk factor for colorectal tumorigenesis in this model. However, the correlation coefficient was higher in Snark(+/-) mice. Moreover, AOM-induced ACF formation was also enhanced in preobese Snark(+/-) mice. Together, these findings suggest that AOM-induced tumorigenesis in Snark(+/-) mice was enhanced via obesity-dependent and -independent mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.